Axon Enterprise (NASDAQ:AXON – Get Rating) had its price target increased by Credit Suisse Group from $134.00 to $142.00 in a research note released on Wednesday morning, The Fly reports. The firm currently has an outperform rating on the biotechnology company's stock.
A number of other research firms have also weighed in on AXON. JMP Securities restated a buy rating and set a $195.00 target price on shares of Axon Enterprise in a research note on Wednesday, June 1st. Northland Securities dropped their price target on shares of Axon Enterprise from $180.00 to $130.00 in a research note on Thursday, May 12th. StockNews.com upgraded shares of Axon Enterprise from a hold rating to a buy rating in a research note on Saturday, June 18th. Robert W. Baird dropped their price target on shares of Axon Enterprise from $145.00 to $125.00 in a research note on Wednesday, May 11th. Finally, Morgan Stanley lowered shares of Axon Enterprise from an overweight rating to an equal weight rating and set a $120.00 price target on the stock. in a research note on Monday, May 23rd. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus price target of $163.25.
Get
Axon Enterprise alerts:
Axon Enterprise Trading Down 0.3 %
NASDAQ:AXON traded down $0.36 on Wednesday, reaching $125.71. 3,253 shares of the company's stock were exchanged, compared to its average volume of 272,527. The company has a quick ratio of 2.18, a current ratio of 2.43 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $8.93 billion, a price-to-earnings ratio of 64.65 and a beta of 0.66. The business has a fifty day moving average of $97.61 and a 200-day moving average of $112.50. Axon Enterprise has a 52-week low of $82.49 and a 52-week high of $209.00.
Axon Enterprise (NASDAQ:AXON – Get Rating) last released its earnings results on Tuesday, August 9th. The biotechnology company reported $0.44 earnings per share for the quarter, topping analysts' consensus estimates of $0.39 by $0.05. Axon Enterprise had a net
margin of 14.20% and a return on equity of 12.86%. The firm had revenue of $285.61 million for the quarter, compared to analyst estimates of $258.96 million. During the same period in the prior year, the firm earned ($0.72) earnings per share. The business's quarterly revenue was up 30.5% compared to the same quarter last year. As a group, analysts expect that Axon Enterprise will post 1.35 earnings per share for the current year.
Insider Buying and Selling at Axon Enterprise
In other news, Director Mark W. Kroll sold 3,159 shares of the firm's stock in a transaction on Wednesday, June 8th. The stock was sold at an average price of $102.82, for a total value of $324,808.38. Following the completion of the transaction, the director now owns 13,691 shares in the company, valued at $1,407,708.62. The sale was disclosed in a document filed with the SEC, which is available at this link. 6.90% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in AXON. Capital International Investors increased its position in Axon Enterprise by 605.2% during the 1st quarter. Capital International Investors now owns 2,660,634 shares of the biotechnology company's stock worth $366,449,000 after purchasing an additional 2,283,343 shares in the last quarter. BlackRock Inc. increased its position in Axon Enterprise by 6.2% during the 4th quarter. BlackRock Inc. now owns 7,366,629 shares of the biotechnology company's stock worth $1,156,559,000 after purchasing an additional 426,830 shares in the last quarter. William Blair Investment Management LLC increased its position in Axon Enterprise by 22.2% during the 2nd quarter. William Blair Investment Management LLC now owns 2,130,903 shares of the biotechnology company's stock worth $198,536,000 after purchasing an additional 386,861 shares in the last quarter. State Street Corp increased its position in Axon Enterprise by 13.3% during the 1st quarter. State Street Corp now owns 2,220,692 shares of the biotechnology company's stock worth $305,856,000 after purchasing an additional 261,508 shares in the last quarter. Finally, Capital Group International Inc. CA boosted its stake in Axon Enterprise by 263.6% in the 1st quarter. Capital Group International Inc. CA now owns 286,404 shares of the biotechnology company's stock worth $39,446,000 after buying an additional 207,638 shares during the last quarter. Hedge funds and other institutional investors own 72.06% of the company's stock.
About Axon Enterprise
(Get Rating)
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, TASER, and Software and Sensors. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Further Reading
- Get a free copy of the StockNews.com research report on Axon Enterprise (AXON)
- Find and Profitably Trade Stocks at 52-Week Lows
- Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
- Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
- 3 Stable Growth Stocks for Bumpy Times
- Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.
